volume 2, issue 8, PS508-S509 2007
DOI: 10.1097/01.jto.0000283511.51667.66
View full text
|
|
Share

Abstract: Gefitinib, a specific inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK), has shown promising activity in lung cancer. However, tumor cells eventually acquire the resistance limiting duration of efficacy. To characterize lung cancer cells with the acquired resistance to gefitinib, a resistant subline HCC827/GR was established by repeated exposure to the drug for more than 6 months. Compared with parent HCC827 cells having delE746-A750 mutation, HCC827/ GR cells were 5676.8-fold more resist…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals